SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001104659-23-019448
Filing Date
2023-02-13
Accepted
2023-02-13 13:33:26
Documents
2
Group Members
ANTOINE PAPIERNIKGRAZIANO SEGHEZZIHENRIJETTE RICHTERMAINA BHAMANMONIQUE SAULNIERSOFINNOVA PARTNERS SAS

Document Format Files

Seq Description Document Type Size
1 SC 13D tm236517d1_sc13d.htm SC 13D 139080
2 EXHIBIT 99.1 tm236517d1_ex99-1.htm EX-99.1 10955
  Complete submission text file 0001104659-23-019448.txt   151639
Mailing Address 7-11 BOULEVARD HAUSSMANN PARIS I0 75009
Business Address 7-11 BOULEVARD HAUSSMANN PARIS I0 75009 33(0)1 76 23 41 00
Sofinnova Capital IX (Filed by) CIK: 0001849915 (see all company filings)

IRS No.: 981517485 | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 230 THIRD AVE., 6TH FLOOR WALTHAM MA 02451
Business Address 230 THIRD AVE., 6TH FLOOR WALTHAM MA 02451 8445311834
CinCor Pharma, Inc. (Subject) CIK: 0001868734 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-93228 | Film No.: 23616663
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences